FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/논문
연구 도서관으로 돌아가기
PubMedReview인간 피험자

Role of circadian CLOCK signaling in cellular senescence.

Yuan Ziyou, Nepovimova Eugenie, Wu Qinghua, Kuca Kamil
Biogerontology2025DOI: 10.1007/s10522-025-10319-7

품질 점수

7/10

참조 문헌

0

피험자

인간

Peptide Contacts 분석

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of the peptides studied in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for these peptides. If you're tracking the research landscape for these compounds, this paper deserves a close read.

주요 발견

The review highlights the role of CLOCK protein in cellular senescence and aging, detailing its dual function in normal cells versus tumor cells. It also discusses how gut microbiota-derived AhR signals can disrupt circadian rhythms and how CLOCK interacts with mTOR and NF-κB pathways to regulate autophagy.

제한 사항

As a review paper, it synthesizes existing literature but does not present new experimental data or primary research findings.

이 연구를 어떻게 해석해야 하는지

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts 분석

An article could focus on how the CLOCK protein's role in cellular senescence and aging provides a promising target for developing new anti-aging therapies, emphasizing the potential of circadian rhythm modulation.

The Clockwork of Aging: How Circadian Rhythms Influence Cellular Senescence

Published: May 16, 2026 | Source: Biogerontology (2025) | Category: Peptide Therapy and Aging Research

Overview

A recent review in Biogerontology highlights the critical role of circadian rhythm regulation by the CLOCK protein in cellular senescence. This research underscores the potential for developing new anti-aging therapies that target circadian mechanisms, offering a fresh perspective on how our biological clocks influence aging at the cellular level.

Study Background

The circadian clock is an internal timekeeping system that regulates various physiological processes to align with Earth's 24-hour light-dark cycle. Disruptions in this rhythm have been linked to accelerated aging and age-related diseases such as cancer, metabolic disorders, and neurodegeneration. The CLOCK protein, a key component of the circadian machinery, has emerged as a central player in cellular senescence, which is the process by which cells lose their ability to divide and function properly.

Researchers aimed to synthesize existing knowledge on how CLOCK regulates gene transcription related to tissue homeostasis, DNA repair, and metabolism. The review also explores how disruptions in circadian rhythms due to environmental factors (like gut microbiota signals) or genetic alterations can lead to accelerated aging and cancer progression.

What the Research Found

The review reveals that CLOCK plays a dual role: it supports cellular rejuvenation by activating DNA repair mechanisms like XPA, thereby maintaining tissue health. However, in tumor cells, CLOCK signaling is often hijacked by oncogenic drivers such as c-MYC and Pdia3, which inhibit telomere shortening and cellular senescence, promoting uncontrolled cell proliferation.

Moreover, the study found that gut microbiota-derived aryl hydrocarbon receptor (AhR) signals can disrupt the CLOCK-BMAL1 complex, leading to circadian rhythm disturbances. This disruption affects autophagy regulation through interactions with mTOR and NF-κB pathways, impacting tissue function and contributing to aging-related pathologies.

What This Means for Peptide Users

While this review does not directly address peptide therapy, it provides a deeper understanding of the molecular mechanisms underlying cellular senescence. For those interested in peptides that target aging processes, such as those involved in DNA repair or metabolism regulation, these findings suggest potential new avenues for therapeutic intervention by modulating circadian rhythms.

Limitations and Caveats

As this is a review paper synthesizing existing literature rather than presenting new experimental data, the conclusions are based on previously published studies. The review does not provide novel empirical evidence but highlights gaps in our understanding of how CLOCK signaling can be therapeutically targeted to slow down aging processes. Additionally, while promising, the potential for anti-aging therapies based on circadian rhythm modulation remains speculative until further clinical trials and experimental validation.

How This Compares to Previous Research

This review builds upon earlier studies that have linked disruptions in circadian rhythms with accelerated aging and age-related diseases. However, it provides a more comprehensive analysis of how CLOCK signaling interacts with various cellular pathways to influence senescence. The dual role of CLOCK in both normal cells and tumor cells is particularly novel and offers new insights into the complex interplay between circadian regulation and cancer biology.

Our Analysis

PeptideVault's assessment of this review highlights its value as a synthesis of current knowledge on circadian rhythm regulation by CLOCK protein and its implications for aging. The paper effectively bridges gaps in understanding how disruptions in circadian rhythms contribute to cellular senescence, providing a solid foundation for future research aimed at developing anti-aging therapies.

Key Takeaways

  • CLOCK Protein's Dual Role: Understanding the dual role of CLOCK in both promoting DNA repair and supporting tumor growth provides new insights into aging mechanisms.
  • Gut Microbiota Influence: The impact of gut microbiota-derived AhR signals on circadian rhythms underscores the importance of considering environmental factors in aging research.
  • Therapeutic Potential: Modulating circadian rhythms through targeted therapies could offer a promising approach to slowing down cellular senescence and age-related diseases.

Original Source

Citation: Yuan Ziyou, Nepovimova Eugenie, Wu Qinghua et al. (2025). Role of circadian CLOCK signaling in cellular senescence.. Biogerontology. DOI: 10.1007/s10522-025-10319-7

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

Peptide Contacts 연구 팀은 복잡한 발견을 피테이드 커뮤니티에게 이해하기 쉬운 언어로 작성했습니다. 항상 원문의 전체 방법론과 데이터를 참조하십시오.

참조 문헌

Yuan Ziyou, Nepovimova Eugenie, Wu Qinghua et al.. (2025). Role of circadian CLOCK signaling in cellular senescence.. Biogerontology. https://doi.org/10.1007/s10522-025-10319-7

PubMed에서 전체 텍스트 확인하기

관련 논문

더 알아보기

이 내용은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.